Department of Surgery, NYU Langone Health, New York, New York.
Gift of Life Donor Program, Philadelphia, Pennsylvania, USA.
Curr Opin Organ Transplant. 2023 Jun 1;28(3):197-206. doi: 10.1097/MOT.0000000000001060. Epub 2023 Mar 9.
The deceased donor organ pool has broadened beyond young, otherwise healthy head trauma victims. But an abundance of donated organs only benefits patients if they are accepted, expeditiously transported and actually transplanted. This review focuses on postdonation challenges and opportunities to increase the number of transplants through improved organ utilization.
We build upon recently proposed changes in terminology for measuring organ utilization. Among organs recovered for transplant, the nonuse rate (NUR REC ) has risen above 25% for kidneys and pancreata. Among donors, the nonuse rate (NUR DON ) has risen to 40% for livers and exceeds 70% for thoracic organs. Programme-level variation in offer acceptance rates vastly exceeds variation in the traditional, 1-year survival benchmark. Key opportunities to boost utilization include donation after circulatory death and hepatitis C virus (HCV)+ organs; acute kidney injury and suboptimal biopsy kidneys; older and steatotic livers.
Underutilization of less-than-ideal, yet transplant-worthy organs remains an obstacle to maximizing the impact of the U.S. transplant system. The increased risk of inferior posttransplant outcomes must always be weighed against the risks of remaining on the waitlist. Advanced perfusion technologies; tuning allocation systems for placement efficiency; and data-driven clinical decision support have the potential to increase utilization of medically complex organs.
已故供体器官库已扩大至不仅限于年轻、健康的头部创伤受害者。但是,如果捐赠的器官被接受、迅速运输并实际移植,那么器官的大量供应才会使患者受益。本综述重点介绍了通过提高器官利用率来增加移植数量的捐赠后挑战和机会。
我们以最近提出的用于衡量器官利用率的术语变化为基础。在可用于移植的器官中,肾脏和胰腺的未使用率(NUR REC)已超过 25%。在供体中,肝脏的未使用率(NUR DON)已上升至 40%,而胸部器官的未使用率超过 70%。在器官接受率方面,项目层面的差异远远超过传统的 1 年生存率基准的差异。提高利用率的主要机会包括心脏死亡后的捐赠和丙型肝炎病毒(HCV)+器官;急性肾损伤和活检肾脏功能不佳;年龄较大和脂肪变性的肝脏。
未能充分利用质量尚可但仍适合移植的器官仍然是美国移植系统充分发挥作用的障碍。必须始终权衡较差的移植后结果的风险与继续在等待名单上的风险。先进的灌注技术;调整分配系统以提高配置效率;以及数据驱动的临床决策支持,都有可能提高对复杂器官的利用率。